Is Fortinet's FortiGuard AI Service Becoming a Key Growth Driver?
Fortinet 's FTNT FortiGuard AI-powered security services have been gaining traction as more enterprises turn to real-time, automated protection to secure users, data and infrastructure. These services, which include threat intelligence, intrusion prevention, data loss prevention (DLP), antivirus and web filtering, are powered by FortiGuard Labs' global sensor network and AI models.
Strong adoption has been driving top-line growth. In the first quarter of fiscal 2025, service revenues of $1.08 billion increased 14% year over year. Security subscriptions, including FortiGuard services, grew 16% year over year and remain a key driver of service growth. It made up 57.7% of Fortinet's service revenues in the first quarter. Services now make up more than 70% of Fortinet's total revenues, underscoring the importance of recurring, AI-powered solutions in its business model.
Fortinet's continued focus on expanding FortiGuard's reach is visible in the launch of its AI-powered Workspace Security Suite. The suite protects key productivity platforms like Microsoft 365 and Google Workspace with AI-based phishing detection, impersonation defense, DLP and 24/7 incident response. These capabilities are fully backed by FortiGuard's intelligence and seamlessly integrate into Fortinet's broader Security Fabric to automate threat response and improve detection accuracy.
Fortinet's AI services are a long-term growth driver. The company is deepening AI integration across its service portfolio and holds more than 500 AI-related patents. As demand grows for scalable, intelligence-led protection across hybrid and cloud environments, Fortinet expects its AI-enhanced services, such as FortiGuard, to contribute meaningfully to recurring, high-margin revenue growth.
FTNT Faces Stiff Competition
Fortinet's FortiGuard AI-powered services face growing competition from Palo Alto Networks PANW and Cisco Systems CSCO, both of which are expanding their AI security capabilities.
Palo Alto Networks is expanding its AI security footprint with the acquisition of Protect AI, a leader in securing AI and ML applications. The move strengthens Palo Alto Networks' capabilities to defend against emerging threats like model manipulation and prompt injection. It reflects the company's push to lead in next-generation cybersecurity by addressing risks in the growing AI ecosystem.
Meanwhile, Cisco Systems is boosting its AI security capabilities with updates to its XDR and Splunk platforms. It introduced agentic AI for faster threat detection and launched Foundation AI, featuring the first reasoning model for security. Cisco Systems also expanded its partnership with ServiceNow to support secure, scalable AI adoption.
FTNT's Share Price Performance, Valuation and Estimates
FTNT shares have risen 9.8% in the year-to-date (YTD) period, underperforming the Zacks Security industry's growth of 21.9%. FTNT has outperformed the Zacks Computer and Technology sector's return of 1.3%.
FTNT's YTD Price Performance
From a valuation standpoint, Fortinet stock is currently trading at a Price/Book ratio of 40.88X compared with the industry's 24.58X. FTNT has a Value Score of F.
FTNT Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 59 cents per share, unchanged over the past 30 days, indicating 3.51% year-over-year growth.
The consensus mark for 2025 earnings is pegged at $2.48 per share, which has been revised upward by 2 cents over the past 30 days. The estimate indicates 4.64% year-over-year growth.
Fortinet currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cisco Systems, Inc. (CSCO): Free Stock Analysis Report
Fortinet, Inc. (FTNT): Free Stock Analysis Report
Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Russia Data Center Market Investment to Reach $2.47 Billion by 2030- Exclusive Research Report by Arizton
"Russia Data Center Market Research Report by Arizton" Get Insights on 97 Existing Data Centers Facilities across Russia According to Arizton's latest research report, the Russia data center market is growing at a CAGR of 9.40% during 2024-2030. Report Scope: Market Size (Investment): USD 2.47 Billion (2030) Market Size (Area): 507 Thousand Sq. Feet (2030) Market Size (Power Capacity): 118 Mw (2030) CAGR - Investment (2024-2030): 9.40% Colocation Market Size (Revenue): USD 1.26 Billion (2030) Historic Year: 2021-2023 Base Year: 2024 Forecast Year: 2025-2030 Market Overview The Russia data center market is experiencing remarkable growth, driven by increasing cloud adoption, rapid digitalization, and the integration of advanced technologies such as artificial intelligence (AI) and machine learning (ML). The Russian government is playing a pivotal role in this expansion through several strategic initiatives. Notably, the Ministry of Digital Development has launched the 'Coordination Center for Data Centers and Cloud Technologies' under the Autonomous Non-Commercial Organization (ANO). This initiative aims to support data center operators by offering loans at interest rates slightly above 5%, enabling the expansion of data center infrastructure across the country. Furthermore, local construction contractors and data center operators are expanding their services to meet the growing demand for colocation, attracting new market entrants and encouraging further investment in state-of-the-art facilities. This surge in activity highlights the Russia data center market's vibrant outlook, underpinned by technological innovation and proactive government support, positioning the country as a key player in the global digital infrastructure landscape. Russia Accelerates 5G Rollout, Fueling Data Center Growth and Digital Innovation Russia is steadily advancing its 4G and 5G infrastructure, paving the way for a nationwide surge in data center investments. As mobile data consumption rises, telecom operators and digital service providers are under increasing pressure to reduce latency and boost real-time processing capabilities. Supporting this digital transformation, the Russian government has introduced strategic initiatives, most notably the Strategy for the Development of the Communications Industry in the Russian Federation for 2024–2035. In addition to outlining a long-term roadmap, the plan includes financial incentives and targeted funding to accelerate 4G and 5G deployment across the country. Complementing these efforts, leading telecom providers such as MTS, MegaFon, and Beeline are actively investing in high-bandwidth, low-latency services to meet the evolving needs of consumers and industries. As 5G infrastructure scales, demand for edge data centers is set to grow significantly. These facilities will play a critical role in enabling local data processing, reducing latency, and delivering seamless, high-performance digital experiences, supporting Russia's vision for smart cities, autonomous technologies, and Industry 4.0. Recent Market News In July 2024, Rostelecom, a Russian telecommunications provider, planned to acquire a data center facility in Moscow, operated by PNK Group; the IT capacity of the facility was slated to be over 72 MW In August 2024, Rostelecom, a Russian data center operator, acquired a data center facility in Medvedkovo, Russia, from 3Data for an investment of over $287 million In April 2025, Yandex decided to develop a new data center facility in Mozhaisk, Russia, for an investment of over $192.93 million. The project will be developed near the village of Zachatye. Sustainability Initiatives Drive Surge in Data Center Investments Across Russia As sustainability becomes a central priority in global infrastructure development, the data center industry is experiencing a growing wave of investment driven by environmentally responsible practices. With data centers known for their high energy consumption, investors are increasingly favoring facilities that embrace green technologies to reduce both environmental impact and long-term operational costs. In Russia, data center operators are capitalizing on the country's natural climate advantages by adopting energy-efficient cooling technologies, most notably, free-cooling systems that utilize ambient cold air. These efforts have helped facilities achieve power usage effectiveness (PUE) ratios as low as 1.5, signaling significant improvements in energy efficiency. Further supporting this sustainable shift, Russia generated approximately 21% of its electricity from renewable sources in 2023, according to the International Renewable Energy Agency (IRENA). Hydropower dominated this mix, contributing over 89% of total renewable output, followed by solar, wind, and biomass energy. Looking ahead, renewable energy adoption in Russia is expected to rise substantially, backed by government support and favorable policies. As a result, the data center sector is poised for further expansion, attracting increased investment from stakeholders focused on long-term sustainability and climate-conscious growth. Moscow Strengthens Its Position in Russia's Data Center Market Moscow continues to solidify its status as Russia's leading hub for data center development, supported by its strong digital economy and advanced infrastructure. In May 2025, the Moscow Internet Exchange (MSK-IX) reported an average internet traffic of approximately 4,545 Gbps, underscoring the city's vital role in national connectivity. Hosting over 58 data centers, Moscow boasts the largest and most diverse network of facilities in the country, with major providers including DataPro, IXcellerate, Telehouse, Selectel, DataSpace, Rostelecom, and 3Data. The presence of large enterprises in finance, media, and retail further fuels demand for cloud services and cutting-edge technologies such as AI, big data, and the Internet of Things. Key Company Profiles IT Infrastructure Providers Fujitsu Huawei Technologies IBM Juniper Networks Lenovo NetApp Supermicro Data Center Construction Contractors & Sub-Contractors Arup Astron Buildings DCDeployed Granlund Group Green MDC Haka Moscow Hexatronic Group LANIT-projects MonArch Group Nefteresurs Sirius Sintec TECEZE XYZ Realty Support Infrastructure Providers Aksa Power Generation Baudouin Bray International Carrier Centiel Climate Technologies Climaveneta CNC Electric CSBattery ENERGY Cyber Power Systems Delta Electronics EMICON FG Wilson GE Vernova HiRef HITEC Power Protection KyotoCooling MIROTEK Mitsubishi Electric Parus Electro Perkins Engine Rehlko Riello Elettronica Group Saft Shanghai Shenglin M&E Technology Socomec Group SVC Smart Voltage Control Teksan Tempesto Group Toshiba Vertiv HTS-Hosser Telecom Solutions KB BOREY Data Center Investors 3Data Atomdata (Rosatom) DataPro IXcellerate Key Point Linxdatacenter MTS OBIT Rostelecom Selectel Yandex DataHouse New Entrants Liberum Navitas X5 Group Market Segmentation & Forecasts IT Infrastructure Servers Storage Systems Network Infrastructure Electrical Infrastructure UPS Systems Generators Transfer Switches & Switchgears PDUs Other Electrical Infrastructure Mechanical Infrastructure Cooling Systems Rack Cabinets Other Mechanical Infrastructure Cooling Systems CRAC & CRAH Units Chiller Units Cooling Towers, Condensers & Dry Coolers Other Cooling Units General Construction Core & Shell Development Installation & Commissioning Services Engineering & Building Design Fire Detection & Suppression Systems Physical Security Data Center Infrastructure Management (DCIM) Tier Standard Tier I & Tier II Tier III Tier IV Geography Moscow Other Cities Why Should you Buy this Research? This research provides a comprehensive analysis of the Russian data center market, covering key factors such as investment size, facility area, power capacity, and colocation market revenue. It offers detailed insights into data center investments by colocation, hyperscale, and enterprise operators across more than 13 cities, including existing and upcoming facilities. The report examines market trends, growth opportunities, and challenges, supported by a clear assessment of IT load capacity and area developments. It also includes a thorough overview of retail and wholesale colocation pricing, along with forecasts through 2030. Additionally, the study highlights the roles of leading IT infrastructure providers, construction contractors, and investors, supported by a transparent research methodology focused on supply and demand dynamics. This makes the report a valuable tool for anyone looking to understand or invest in Russia's evolving data center landscape. Japan Data Center Market - Investment Analysis & Growth Opportunities 2025-2030 China Data Center Market - Investment Analysis & Growth Opportunities 2025-2030 What Key Findings Will Our Research Analysis Reveal? How big is the Russia data center market? How much MW of power capacity will be added across Russia during 2025-2030? How many existing and upcoming data center facilities exist in Russia? What is the growth rate of the Russia data center market? What factors are driving the Russian data center market? Who are the key investors in the Russian data center market? Why Arizton? 100% Customer Satisfaction 24x7 availability – we are always there when you need us 200+ Fortune 500 Companies trust Arizton's report 80% of our reports are exclusive and first in the industry 100% more data and analysis 1500+ reports published till date Post-Purchase Benefit 1hr of free analyst discussion 10% off on customization About Us: Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Globe and Mail
an hour ago
- Globe and Mail
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant ( s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Globe and Mail
an hour ago
- Globe and Mail
Spinal Muscular Atrophy Pipeline Drugs Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight
"Spinal Muscular Atrophy Pipeline" Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals, CANbridge Pharmaceuticals Inc., Astellas Pharma, Alcyone Therapeutics, Exicure, AndroScience Corporation, Scholar Rock, NMD Pharma, Aurimed Pharma, Biogen, Hanugen Theraputics, and others. (Albany, USA) 'Spinal Muscular Atrophy Pipeline Insight, 2025″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market. The Spinal Muscular Atrophy clinical trials report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report: In March 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with spinal muscular atrophy (SMA) who are receiving an SMN-targeted treatment. The FDA will review the application under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2025. The FDA priority review designation conveys that the FDA has determined that if apitegromab is approved, it could offer significant improvement in the safety or effectiveness of treatment of the serious condition of SMA Spinal Muscular Atrophy Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Leading Spinal Muscular Atrophy companies working in the market are Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others, are developing therapies for the Spinal Muscular Atrophy treatment Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, GYM329, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years. In February 2025, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam) tablet for people living with spinal muscular atrophy (SMA). Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. In January 2025, Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). On April 2024, Hoffmann-La Roche announced a Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy On April 2024, Genentech announced results of a multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments. On April 2024, Biogen announced results of a study whose primary objective is to examine the clinical efficacy of nusinersen administered intrathecally at higher doses to participants with spinal muscular atrophy (SMA), as measured by change in Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders (CHOP-INTEND) total score (Part B); to examine the safety and tolerability of nusinersen administered intrathecally at higher doses to participants with SMA (Parts A and C). On January 2024, Novartis announced results of a Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®). On January 2024, NMD Pharma A/S announced results of a Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy On December 2023, Novartis announced results of a Long-term Safety Study in Brazilian Patients With a Confirmed Diagnosis of Spinal Muscular Atrophy (SMA) Treated With Onasemnogene Abeparvovec (Zolgensma®) – ARISER Study. On May 2023, Biogen announced results of a study whose primary objective is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA) Spinal Muscular Atrophy Overview Spinal Muscular Atrophy (SMA) is a rare genetic neuromuscular disorder that affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 (Survival Motor Neuron 1) gene, which results in reduced levels of the SMN protein essential for motor neuron survival. The severity of SMA varies, and it is classified into different types (SMA 0–4) based on age of onset and disease progression. Spinal Muscular Atrophy primarily affects voluntary muscles, particularly those involved in movement, breathing, and swallowing. Spinal Muscular Atrophy Symptoms range from severe muscle weakness in infancy (SMA Type 1, the most common and severe form) to milder symptoms with later onset (SMA Type 3 and 4). In severe cases, respiratory complications can be life-threatening. Spinal Muscular Atrophy Diagnosis is confirmed through genetic testing. While there is no cure, disease-modifying therapies like nusinersen (Spinraza), risdiplam (Evrysdi), and gene therapy with onasemnogene abeparvovec (Zolgensma) can improve motor function and survival. Supportive care, including physical therapy, respiratory support, and nutritional management, plays a crucial role in improving the quality of life. Spinal Muscular Atrophy Advancements in treatment and early intervention, especially through newborn screening, have significantly improved outcomes for individuals with SMA. Spinal Muscular Atrophy Pipeline Therapeutics Assessment DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include: ACTX-401: Novartis Apitegromab: Scholar Rock GYM329: Roche And Many Others Spinal Muscular Atrophy Pipeline Analysis: The Spinal Muscular Atrophy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment. Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies @ Spinal Muscular Atrophy Companies and Drugs Scope of Spinal Muscular Atrophy Pipeline Drug Insight Coverage: Global Key Spinal Muscular Atrophy Companies: Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, and others Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers Table of Contents Spinal Muscular Atrophy Report Introduction Spinal Muscular Atrophy Executive Summary Spinal Muscular Atrophy Overview Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment Spinal Muscular Atrophy Pipeline Therapeutics Spinal Muscular Atrophy Late Stage Products (Phase II/III) Spinal Muscular Atrophy Mid Stage Products (Phase II) Spinal Muscular Atrophy Early Stage Products (Phase I) Spinal Muscular Atrophy Preclinical Stage Products Spinal Muscular Atrophy Therapeutics Assessment Spinal Muscular Atrophy Inactive Products Company-University Collaborations (Licensing/Partnering) Analysis Spinal Muscular Atrophy Key Companies Spinal Muscular Atrophy Key Products Spinal Muscular Atrophy Unmet Needs Spinal Muscular Atrophy Market Drivers and Barriers Spinal Muscular Atrophy Future Perspectives and Conclusion Spinal Muscular Atrophy Analyst Views Appendix About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
